Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Epigral Ltd (EPIGRAL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543332 NSE: EPIGRAL Chemicals | Small Cap | Epigral Share Price
₹1,100.50 -9.70 (-0.87%)
As on 22-Sep'26 16:59
Epigral Ltd (EPIGRAL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543332 NSE: EPIGRAL Chemicals | Small Cap | Epigral Share Price
₹1,100.50 -9.70 (-0.87%)
As on 22-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹4,748 Cr.
Current Price
₹1,100.5
52-Week Low / High
₹806 / 1,767
TTM EPS
₹62.8
TTM Sales
₹2,626 Cr.
Book Value per Share
₹537.9
P/E Ratio
17.52
Lower than its 5-year historical median
Industry PE
48.3
Price to Book (P/B)
2.05
Lower than its 5-year historical median
Price to Sales (P/S)
1.81
Lower than its 5-year historical median
EV/EBITDA
8.94
Lower than its 5-year historical median
Dividend Yield
0.45%
Profitability Efficiency
Return on Equity (ROE)
16.09%
Outperforms industry median
Return on Capital Employed (ROCE)
15.65%
Outperforms industry median
Return on Assets (ROA)
9.97%
Operating Profit Margin
22.4%
Net Profit Margin
13.14%
Gross Profit Margin
19.1%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-0.9%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-20.21%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
-7.19%
Asset Quality
Promoter Holding
68.83%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹2,277 Cr.
Equity
₹43.1 Cr.
Face Value
₹10
All Time Low / High
₹386.35 / 2408.35
Check Before You Invest
Quality
Very GoodValuation
UndervaluedCheck Valuation charts
Price Trend
Semi Strong
Is Epigral Ltd a good quality company?
Epigral Ltd is a good quality company, based on a consistently good multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Epigral Ltd performance compare with that of its Peers?
Revenue growth of Epigral Ltd vs industry peers?
Epigral Ltd revenue CAGR is 24.99%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Epigral Ltd?
Promoters hold 68.83% of the Epigral Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Epigral Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 9.71% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Epigral Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 18.5% | 37.9% | 36.9% | 15.9% | 16.7% | 29.4% | 32.2% | 17.5% | 25.2% | 15.7% | - |
| Value Creation Index ⓘ | 0.3 | 1.7 | 1.6 | 0.1 | 0.2 | 1.1 | 1.3 | 0.3 | 0.9 | 0.1 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 392 | 598 | 710 | 611 | 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,527 | 2,626 |
| Sales YoY Gr. | - | 52.6% | 18.9% | -14.1% | 35.7% | 87.2% | 41.1% | -11.8% | 32.2% | -0.9% | - |
| Adj EPS ⓘ | 9.3 | 22 | 43.5 | 26.7 | 24 | 60.4 | 84.1 | 46.3 | 80.6 | 75.9 | 63 |
| YoY Gr. | - | 135.2% | 97.8% | -38.5% | -10.1% | 151.3% | 39.4% | -45% | 74.1% | -5.9% | - |
| BVPS (₹) ⓘ | 51.1 | 73.1 | 68.4 | 89.7 | 113.9 | 174.7 | 257.3 | 301.8 | 441.2 | 514.9 | 537.9 |
| Adj Net Profit ⓘ | 66.1 | 155 | 179 | 111 | 99.8 | 251 | 350 | 192 | 348 | 327 | 272 |
| Cash Flow from Ops. ⓘ | 138 | 225 | 261 | 165 | 229 | 284 | 626 | 398 | 441 | 436 | - |
| Debt/CF from Ops. ⓘ | 0.9 | 0.3 | 1.5 | 3.2 | 2.4 | 3.5 | 1.4 | 2.4 | 1.3 | 1.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 23% | 25% | 4.9% | -0.9% | ||||
| Adj EPS ⓘ | 26.2% | 25.9% | -3.4% | -5.9% | ||||
| BVPSⓘ | 29.3% | 35.2% | 26% | 16.7% | ||||
| Share Price | - | 8.9% | 3.7% | -36.5% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 20.1 | 35.4 | 35.4 | 20.6 | 15.8 | 35.6 | 39 | 16.6 | 22 | 15.9 | 12 |
| Op. Profit Mgn % ⓘ | 36.8 | 42.7 | 43.9 | 31.8 | 31.5 | 32.9 | 31.5 | 25 | 27.9 | 22.4 | 22.2 |
| Net Profit Mgn % ⓘ | 16.9 | 26 | 25.2 | 18.2 | 12.1 | 16.2 | 16 | 10 | 13.6 | 13 | 10.4 |
| Debt to Equity ⓘ | 0.3 | 0.1 | 0.8 | 0.9 | 0.8 | 1.4 | 0.8 | 0.8 | 0.3 | 0.3 | - |
| Working Cap Days ⓘ | 81 | 75 | 79 | 84 | 77 | 75 | 69 | 87 | 85 | 112 | 51 |
| Cash Conv. Cycle ⓘ | 35 | 28 | 25 | 34 | 26 | 40 | 41 | 40 | 36 | 56 | 10 |
Valuation of Epigral - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|
| Sales | 829 | 1,551 | 2,188 | 1,929 | 2,550 | 2,527 |
| Operating Expenses ⓘ + | 567 | 1,041 | 1,499 | 1,448 | 1,839 | 1,960 |
| Operating Profit ⓘ | 261 | 509 | 689 | 481 | 711 | 567 |
| Operating Profit Margin (%) | 31.5% | 32.9% | 31.5% | 24.9% | 27.9% | 22.4% |
| Other Income ⓘ + | 7 | 8 | 9 | 7 | 15 | 15 |
| Interest ⓘ | 34 | 48 | 67 | 73 | 53 | 72 |
| Depreciation ⓘ | 74 | 86 | 109 | 124 | 133 | 168 |
| Profit Before Tax ⓘ | 161 | 383 | 522 | 291 | 541 | 341 |
| Tax ⓘ | 60 | 131 | 169 | 95 | 183 | 9 |
| Profit After Tax | 101 | 253 | 353 | 196 | 358 | 332 |
| PAT Margin (%) | 12.2% | 16.3% | 16.1% | 10.2% | 14.0% | 13.1% |
| Adjusted EPS (₹) | 24.3 | 60.8 | 85.0 | 47.1 | 82.9 | 77.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 5.90% | 10.60% | 7.20% | 6.50% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 684 | 726 | 1,069 | 1,254 | 1,905 | 2,221 | |||||
| Debt + | 416 | 848 | 636 | 768 | 498 | 448 | |||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Trade Payables | 73 | 88 | 110 | 184 | 186 | 260 | |||||
| Others Liabilities ⓘ | 276 | 461 | 617 | 588 | 564 | 576 | |||||
| Total Liabilities ⓘ | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,505 | |||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 1,102 | 1,068 | 1,804 | 1,767 | 2,238 | 2,117 | |||||
| CWIP ⓘ | 126 | 589 | 158 | 483 | 64 | 451 | |||||
| Investments ⓘ | 0 | 0 | 21 | 21 | 98 | 23 | |||||
| Inventories | 54 | 154 | 212 | 263 | 388 | 349 | |||||
| Trade Receivables | 119 | 256 | 166 | 179 | 232 | 417 | |||||
| Cash Equivalents | 1 | 25 | 15 | 7 | 22 | 5 | |||||
| Others Assets ⓘ | 47 | 31 | 56 | 76 | 110 | 144 | |||||
| Total Assets ⓘ | 1,449 | 2,124 | 2,432 | 2,794 | 3,152 | 3,505 | |||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 229 | 284 | 626 | 398 | 441 | 436 |
| Cash Flow From Investing Activity ⓘ + | -197 | -455 | -437 | -401 | -262 | -355 |
| Cash Flow From Financing Activity ⓘ + | -32 | 195 | -200 | -8 | -164 | -94 |
| Net Cash Flow ⓘ | 1 | 24 | -11 | -11 | 15 | -14 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 21.31 | 42.16 | 39.36 | 16.86 | 22.65 | 16.09 | ||||
| ROCE (%) | 15.97 | 29.4 | 32.2 | 17.5 | 25.26 | 15.65 | ||||
| Asset Turnover Ratio | 0.59 | 0.9 | 1.02 | 0.77 | 0.91 | 0.8 | ||||
| PAT to CFO Conversion(x) | 2.27 | 1.12 | 1.77 | 2.03 | 1.23 | 1.31 | ||||
| Working Capital Days | ||||||||||
| Receivable Days | 50.60 | 42.70 | 33.30 | 31.40 | 27.90 | 44.30 | ||||
| Inventory Days | 23 | 23.70 | 28.80 | 43.20 | 44.10 | 50.30 | ||||
| Payable Days | 69.20 | 38.60 | 32.50 | 50.60 | 49.80 | 56.90 | ||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Epigral Ltd FAQs
The current trading price of Epigral on 22-Sep-2026 16:59 is ₹1,100.5.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Epigral stood at ₹4,747.7 Cr
The latest P/E ratio of Epigral as of 21-Sep-2026 is 17.47.
The latest P/B ratio of Epigral as of 21-Sep-2026 is 2.05.
The 52-week high of Epigral is ₹1,767.1 and the 52-week low is ₹806.2.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Epigral is ₹2,626 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Epigral Ltd is a good quality company.
The key valuation ratios of Epigral Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Epigral Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Epigral Ltd
Meghmani Finechem Limited (MFL) is a Public Company limited by shares domiciled in India, incorporated under the provisions of Companies Act, 1956. The registered office of the company is located at GIDC Industrial Estate, Dahej, Tal. Vagara, Dist. Bharuch, Gujarat.
It is an ISO 9001 and ISO 14001-certified company founded in 2007 and recognised as one of the leading producers of chlor alkali and its Derivatives with backward and forward integration facilities. The Company meets the global essential chemicals demand with responsible care and with large-scale growth, while committing to quality and environment integrity.
MFL works out of an advanced automated production facility, which is equipped to address international standards in the manufacture of Caustic Soda, Caustic Potash, Chlorine, Hydrogen, Chloromethanes and Hydrogen Peroxide. The Company aims to service domestic as well as export markets, contributing towards the ‘Make in India’ initiative.
Business area of the company
The Company is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products.
You have 47 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
